|
Take heed to this text |
SectionStar is a cutting-edge robotic solution specifically designed for tissue sectioning and switching, engineered to deliver enhanced capabilities, reliability, and consistency. | Supply: Clarapath
While robotics and automation initiatives have gained traction in healthcare, primarily focusing on surgical robots and physical rehabilitation, there remains untapped potential for innovative solutions addressing broader clinical challenges and optimizing patient care. Clarapath Inc. hopes to alter this.
The privately held company headquartered in Hawthorne, New York, announced a significant milestone with its successful raise of $36 million in Collection B-1 funding. Clarapath aims to revolutionize the process of tissue examination in pathology laboratories by modernizing its workflow. This latest round of funding has brought the total amount raised to a staggering $75 million.
The corporation announced that its SectionStar system leverages the power of robotics, artificial intelligence, and automation to revolutionize the processing of tissue samples in laboratories. Following the latest round of funding, Clarapath has announced plans to create and implement a cutting-edge range of robotics, machine vision, and digital automation tools, revolutionizing healthcare standards for hospitals and patients.
Pathology can profit from automation
The discipline of pathology encompasses the meticulous microscopic analysis of cellular and tissue structures, as defined by Clarapath. This foundational research underlies the analysis, therapeutic pathways, and treatment approaches for a vast array of illnesses, including various types of cancer, autoimmune disorders, and degenerative diseases.
Every year, more than 12 million human and veterinary biopsy procedures take place in the United States, with a significant number of additional tests conducted to ensure the safety of biopharmaceutical drugs. According to Clarapath, laboratories are grappling with a multifaceted crisis, characterized by increasing workloads and outdated methods for processing tissue samples.
“For too long, pathology laboratories have lagged behind in terms of expertise innovation, unlike other areas of medicine that have witnessed significant advancements,” said Gregg Sossaman, M.D., chair of pathology and laboratory medicine at Ochsner Health and incoming president of the American Society of Clinical Pathology. “Coupling technical prowess with robotics acumen and healthcare workflow knowledge, Clarapath successfully embodies the ideal blend.”
Clarapath asserts that SectionStar can significantly elevate slide quality, dramatically reduce turnaround time, and effectively curtail costs. | Supply: Clarapath
Clarapath to commercialize SectionStar
Northwell Ventures spearheaded Clarapath’s $45 million Series B-1 funding round, accompanied by a coalition of new strategic investors that included the CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures.
“Innovative thinking is deeply ingrained within our heritage at Northwell,” said Rich Mulry, CEO, “where we proactively seek out cutting-edge solutions that not only advance patient care but also drive down costs.” “We’ve been proud partners with Clarapath for seven years, sharing their bold vision to revolutionize lab medicine. Our commitment to their innovative work remains unwavering, poised to reshape the future of medical diagnostics.”
Clarapath announces its intention to accelerate the commercialization of SectionStar with its newly secured capital. The organization will utilize the funding to enhance its gross revenue, diversify businesses, and refine precision manufacturing processes, while also continuing research and development initiatives.
“With a shared commitment to revolutionize patient care, our strategic buyers join forces with us to transform the long-neglected aspect of healthcare that requires urgent attention,” Eric Feinstein, CEO of Clarapath.
“As labs transition to digital pathology, automating earlier stages becomes crucial to ensure consistent results and deliver high-quality specimens for diagnostic evaluation.” “Our cutting-edge automation and digital tools unlock unprecedented insights, delivering faster results and reduced bias to ultimately benefit patients.”
.
